References
- Rowe TA, McKoy JM. Sepsis in older adults. Infect Dis Clin North Am. 2017;31(4):731–742.
- De Gaudio AR, Rinaldi S, Chelazzi C, et al. Pathophysiology of sepsis in the elderly: clinical impact and therapeutic considerations. Curr Drug Targets. 2009;10(1):60–70.
- Sepsis: recognition, diagnosis and early management: (c) NICE (2017) Sepsis: recognition, diagnosis and early management. BJU Int. 2018;121:497–514.
- De Waele JJ, Dhaese S. Antibiotic stewardship in sepsis management: toward a balanced use of antibiotics for the severely ill patient. Expert Rev anti Infect Ther. 2019;17(2):89–97.
- Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010;11(1):23–36.
- Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): diagnostic, prognostic, and therapeutic applications. Front Oncol. 2018;8:24.
- Hayek SS, Leaf DE, Samman Tahhan A, et al. Soluble urokinase receptor and acute kidney injury. N Engl J Med. 2020;382(5):416–426.
- Song S, Jia Q, Chen X, et al. Serum suPAR associated with disease severity and mortality in elderly patients with community-acquired pneumonia. Scand J Clin Lab Invest. 2020;80(6):515–522.
- Polzik P, Grondal O, Tavenier J, et al. SuPAR correlates with mortality and clinical severity in patients with necrotizing soft-tissue infections: results from a prospective. Sci Rep. 2019;9(1):5098.
- Şirinoğlu M, Soysal A, Karaaslan A, et al. The diagnostic value of soluble urokinase plasminogen activator receptor (suPAR) compared to C-reactive protein (CRP) and procalcitonin (PCT) in children with systemic inflammatory response syndrome (SIRS). J Infect Chemother. 2017;23(1):17–22.
- Chen JS, Chang LC, Wu CZ, et al. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models. J Biomed Sci. 2016;23:24.
- Liu H, Yao S, Dann SM, et al. ERK differentially regulates Th17- and Treg-cell development and contributes to the pathogenesis of colitis. Eur J Immunol. 2013;43(7):1716–1726.
- Zhu J. T helper cell differentiation. Cold Spring Harb Perspect Biol. 2018;10(10):a030338.
- Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810.
- Long D, Wang Y, Wang H, et al. Correlation of serum and ascitic fluid soluble form urokinase plasminogen activator receptor levels with patient complications, disease severity, inflammatory markers, and prognosis in patients with severe acute pancreatitis. Pancreas. 2019;48(3):335–342.
- D'Alonzo D, De Fenza M, Pavone V. COVID-19 and pneumonia: a role for the uPA/uPAR system. Drug Discov Today. 2020;25(8):1528–1534.
- Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 2010;584(9):1923–1930.
- Del Rosso M, Fibbi G, Pucci M, et al. The plasminogen activation system in inflammation. Front Biosci. 2008;13:4667–4686.
- Hirahara K, Nakayama T. CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm. Int Immunol. 2016;28(4):163–171.
- Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases. Biomol Concepts. 2018;9(1):64–79.
- Bedoya SK, Lam B, Lau K, et al. Th17 cells in immunity and autoimmunity. Clin Dev Immunol. 2013;2013:986789.